It is where the most competitive projects are included, the classic collaborative projects from previous Framework Programs and which bring together researchers, companies, research centers and universities.
Eligible actions
- Personalized medicine.
- Conditions of the environment on health and how we affect the environment.
- Address the European Health Plan “One Health” against microbial resistance.
Name | Opening date | Next deadline | Deadline model | Link |
Mission Ocean and Waters and Mission A Soil Deal for Europe – Joint demonstration of approaches and solutions to address nutrient pollution in the landscape-river-sea system in the Mediterranean sea basin | 17 January 2023 | 20 September 2023 | single-stage | |
Maintaining access to regular health and care services in case of cross-border emergencies | 12 January 2023 | 13 April 2023 | single-stage | |
Pandemic preparedness and response: Sustaining established coordination mechanisms for European adaptive platform trials and/or for cohort networks | 12 January 2023 | 13 April 2023 | single-stage | |
Novel approaches for palliative and end-of-life care for non-cancer patients | 12 January 2023 | 13 April 2023 | single-stage | |
Resilience and mental wellbeing of the health and care workforce | 12 January 2023 | 13 April 2023 | single-stage | |
Interventions in city environments to reduce risk of non-communicable disease (Global Alliance for Chronic Diseases – GACD) | 12 January 2023 | 13 April 2023 | single-stage | |
Pandemic preparedness and response: Understanding vaccine induced-immunity | 12 January 2023 | 13 April 2023 | single-stage | |
European Partnership on Rare Diseases | 12 January 2023 | 19 September 2023 | single-stage | |
Health impacts of endocrine-disrupting chemicals: bridging science-policy gaps by addressing persistent scientific uncertainties | 12 January 2023 | 13 April 2023 | single-stage | |
Development and harmonisation of methodologies for assessing digital health technologies in Europe | 12 January 2023 | 13 April 2023 | single-stage | |
Towards structuring brain health research in Europe | 12 January 2023 | 13 April 2023 | single-stage | |
Evidence-based interventions for promotion of mental and physical health in changing working environments (post-pandemic workplaces) | 12 January 2023 | 13 April 2023 | single-stage | |
Clinical trials of combined Advanced Therapy Medicinal Products (ATMPs) | 12 January 2023 | 13 April 2023 | single-stage | |
Better integration and use of health-related real-world and research data, including genomics, for improved clinical outcomes | 12 January 2023 | 13 April 2023 | single-stage | |
Harnessing the potential of real-time data analysis and secure Point-of-Care computing for the benefit of person-centred health and care delivery | 12 January 2023 | 13 April 2023 | single-stage | |
Developing a Data Quality and Utility Label for the European Health Data Space | 12 January 2023 | 13 April 2023 | single-stage | |
Environmentally sustainable and climate neutral health and care systems | 12 January 2023 | 13 April 2023 | single-stage | |
European Partnership on Personalised Medicine | 12 January 2023 | 13 April 2023 | single-stage | |
Pandemic preparedness and response: Broad spectrum anti-viral therapeutics for infectious diseases with epidemic potential | 12 January 2023 | 13 April 2023 | single-stage | |
Pandemic preparedness and response: Immunogenicity of viral proteins of viruses with epidemic and pandemic potential | 12 January 2023 | 13 April 2023 | single-stage | |
Planetary health: understanding the links between environmental degradation and health impacts | 12 January 2023 | 13 April 2023 | single-stage | |
Expanding the European Electronic Health Record exchange Format to improve interoperability within the European Health Data Space | 12 January 2023 | 13 April 2023 | single-stage | |
The Silver Deal – Person-centred health and care in European regions | 12 January 2023 | 13 April 2023 | single-stage | |
Pragmatic clinical trials on minimally invasive diagnostics | 12 January 2023 | 13 April 2023 | single-stage | |
Mapping the hurdles for the clinical applications of Advanced Therapy Medicinal Products (ATMPs) | 12 January 2023 | 13 April 2023 | single-stage | |
Integrated, multi-scale computational models of patient patho-physiology (‘virtual twins’) for personalised disease management | 12 January 2023 | 13 April 2023 | single-stage | |
Supporting the uptake of innovative Health Technology Assessment (HTA) methodology and advancing HTA expertise across EU | 12 January 2023 | 13 April 2023 | single-stage | |
Relationship between infections and non-communicable diseases | 12 January 2023 | 13 April 2023 | single-stage | |
Global coordination of exposome research | 12 January 2023 | 13 April 2023 | single-stage | |
Modelling and simulation to address regulatory needs in the development of orphan and paediatric medicines | 12 January 2023 | 13 April 2023 | single-stage | |
Addressing poorly-understood tumour-host interactions to enhance immune system-centred treatment and care interventions in childhood, adolescent, adult and elderly cancer patients. | 12 January 2023 | 12 April 2023 | single-stage | |
Enhance primary cancer prevention through sustainable behavioural change | 12 January 2023 | 12 April 2023 | single-stage | |
Pandemic preparedness and response: In vitro diagnostic devices to tackle cross-border health threats | 12 January 2023 | 13 April 2023 | single-stage | |
Establish best practices and tools to improve the quality of life for childhood cancer patients, survivors and their families in European regions | 12 January 2023 | 12 April 2023 | single-stage | |
Testing and demonstrating transformative solutions to build resilience towards health risks caused by the effects of climate change | 10 January 2023 | 20 September 2023 | single-stage | |
Strengthening the European translational research ecosystem for advanced therapy medicinal products (ATMPs) for rare diseases | 13 December 2022 | 13 April 2023 | single-stage |
Scope: Europe
Budget: 8.246 M€
Organism: European comission
Aim of the project: R+D projects in the field of Health-
BENEFICIARIES
Any type of organization can apply for funding from Horizon Europe as long as it has the operational and financial capacity to carry out the tasks it proposes.
TYPE AND AMOUNT OF FINANCING
Variable
ELIGIBLE EXPENSES
Direct and indirect costs.